 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (NASDAQ:PSNL  Get Free Report) and WuXi AppTec (OTCMKTS:WUXAY  Get Free Report) are both medical companies, but which is the superior investment? We will compare the two...

Reviewing WuXi AppTec (OTCMKTS:WUXAY) & Personalis (NASDAQ:PSNL)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21st Annual Morgan Stanley Global Healthcare...

Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, between the dates of May 15, 2023 and August 15, 2023, non-qualified stock options to purchase an aggregate of 43,000 shares of its common...

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is...

Sidoti Events, LLCs Virtual August Micro-Cap Conference

Personalis, Inc. (NASDAQ:PSNL  Free Report)  HC Wainwright decreased their Q3 2023 EPS estimates for Personalis in a report issued on Wednesday, August 9th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.53) for the quarter, down...

Q3 2023 EPS Estimates for Personalis, Inc. Lowered by HC Wainwright (NASDAQ:PSNL)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC Research Report) and Pe... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Revance Therapeutics (RVNC), Personalis (PSNL)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center Hospital East and...

Personalis Reports Second Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m...

Personalis to Announce Second Quarter 2023 Financial Results

Personalis, Inc. ( NASDAQ:PSNL ) shareholders should be happy to see the share price up 28% in the last week. But the...

Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of three-year loss

Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Personalis is seeking injunctive relief and monetary damages. This suit brings the total number of patents that Personalis alleges Foresight Diagnostics...

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Watchers	1,941
52-Wk Low	$1.20
52-Wk High	$4.31

Market Cap	$59.19M
Volume (M)	849.00
52-Wk High	$4.31
52-Wk Low	$1.20

PSNL Personalis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals